The Hidden Inflammatory Trigger: New UNC Research Links Dietary Oxalate to IBD Severity on September 20, 2026 Posted by
The Longevity Benchmark: Can You Still Perform These 3 Classic Strength Moves After 60? on September 20, 2026 Posted by
The Politicization of the Stethoscope: Is Medical Neutrality a Vanishing Virtue? on September 20, 2026 Posted by
The Silent Pandemic: Loneliness Linked to 871,000 Annual Deaths as Experts Call for a “Third Pillar” of Health on September 20, 2026 Posted by
The Hidden Neurobiology of Relapse: Why Abstinence Can Be a Double-Edged Sword in Alcohol Addiction on September 20, 2026 Posted by
Bridging the Gap: How a Two-Decade Partnership is Redefining Medical-Dental Collaboration in Sleep Medicine on September 20, 2026 Posted by
The Silent Epidemic: Understanding and Managing Bunions Through Targeted Foot Mechanics on September 20, 2026 Posted by
The Hidden Inflammatory Trigger: New UNC Research Links Dietary Oxalate to IBD Severity on September 20, 2026 Posted by
The Longevity Benchmark: Can You Still Perform These 3 Classic Strength Moves After 60? on September 20, 2026 Posted by
The Politicization of the Stethoscope: Is Medical Neutrality a Vanishing Virtue? on September 20, 2026 Posted by
The Silent Pandemic: Loneliness Linked to 871,000 Annual Deaths as Experts Call for a “Third Pillar” of Health on September 20, 2026 Posted by
Posted in Cardiovascular Recovery A Potential Paradigm Shift: Baxdrostat Shows Promise in Managing Resistant Hypertension and Chronic Kidney Disease on September 9, 2026
Posted in Cardiovascular Recovery Breakthrough Hypertension Treatment: Baxdrostat Shows Promise in Protecting Kidney Function on September 2, 2026
Posted in Cardiovascular Recovery A Potential Breakthrough: Baxdrostat Shows Promise in Managing Hypertension and Protecting Kidney Function on August 25, 2026
Posted in Cardiovascular Recovery A Potential Breakthrough: Baxdrostat Shows Promise in Managing Hypertension and Kidney Disease on May 20, 2026 rifanmuazin
Posted in Cardiovascular Recovery A New Frontier in Hypertension: FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor on May 19, 2026 rifanmuazin
